In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference ...

Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.

Teva Pharmaceuticals (TEVA) and Alvotech (ALVO) announced the availability of SELARSDI injection in the U.S., a biosimilar to Stelara for the ...

EQS-News: Benzinga / Key word (s): Science Soligenix's Leadership Aims To Drive Growth In Rare Disease Markets In 2025 And ...

Injections should not be administered into psoriasis skin lesions. Signs and symptoms of infection should be reviewed with the patient. Make sure patients understand that an ISR will resolve and ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Local companies are developing technologies that they hope could replace a painful poke with something that feels more like ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...